February 2014 Issue of The Ophthalmologist

Be it battling blindness one patient at a time or changing global healthcare policies, ophthalmologists demonstrate admirable altruism.

An unexpected and simple advance has made stem cell production much easier and safer. Do STAP stem cells bring the treatment, even cure, of ocular disease a lot closer?

Carl Zeiss and Aaren buy, Alimera raise working capital and Novo A/S make a milestone payment to Ophthotech for Fovista.

Google is developing contact lenses that will help patients monitor their glucose status. The technology is not entirely new, but the company’s infrastructure, experience and muscle suggest that it could have a substantial medical and commercial impact.

Received wisdom says that there is a critical period after birth during which the brain is wired for sight; blindness then means blindness for life

In the UK, real-world visual outcomes of patients receiving ranibizumab for neovascular AMD fail to match those achieved in most randomized trials. But they were delivered with substantially fewer injections and hospital visits.

Medscape assessed the lifestyles of physicians; of the twenty-six specialties covered, ophthalmologists have the most to boast about.

The Ophthalmologist Travel Award represents a great opportunity: the chance of a free trip to the AAO 2014 congress in Chicago – flights, accommodation, and congress registration fees, in return for a chronic DME case study.

At the age of 39, I left a satisfying career in the United States to follow a dream of building a world-class eye institute in my native India.

Creation of the anterior capsulorhexis is a key stage in cataract surgery, and producing a precise rhexis is of paramount importance. The most commonly used technique to achieve this during phacoemulsification is continuous curvilinear capsulorhexis (CCC).

Why we need a rethink of the surgical approach to the barrier between the anterior and posterior lens segments

Cataract surgery and IOL implantation have come a long way since the 1990s, and it appears that technical innovations are stoking demand more than medical need.

You can’t predict the future, but a lot can be learned by analyzing what happened in the past.

Can you envisage a future in which deploying a tiny cell-spraying device during vitreoretinal surgery reverses years of retinal cell death? Keith Martin can.

Realizing the full potential of your cataract/ refractive practice starts with marketing… but it doesn’t stop there.

Electronic patient education systems look great, offer flexibility in what’s communicated and can be branded with your logo. Goodbye textbooks!

Sitting Down With Walter Wrobel, CEO/ President, and Reinhard Rubow, CFO, Retina Implant AG